163 results on '"Fernández-Egea, Emilio"'
Search Results
2. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
3. Influence of time to clozapine prescription on the clinical outcome
4. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies
5. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition
6. Anthropometry in antipsychotic-naïve first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples
7. The longitudinal structure of negative symptoms in treatment resistant schizophrenia
8. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina
9. Prefrontal Cortex Activation and Stopping Performance Underlie the Beneficial Effects of Atomoxetine on Response Inhibition in Healthy Volunteers and Those With Cocaine Use Disorder
10. Defining negative symptoms remission in schizophrenia using the Brief Negative Symptom Scale
11. Early versus late risk factors for deficit and nondeficit schizophrenia
12. Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia
13. Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia
14. Structural and functional abnormalities within sensori-motor and limbic networks underpin intermittent explosive symptoms in Tourette disorder
15. The influence of negative and affective symptoms on anhedonia self-report in schizophrenia
16. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice
17. Variación intraindividual en los niveles plasmáticos de clozapina y norclozapina en la práctica clínica
18. An expert Delphi consensus for the characteristics of an ideal clozapine-specific side effect scale
19. Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model
20. A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD
21. Influence of time to clozapine prescription on the clinical outcome
22. Neural basis of impaired safety signaling in Obsessive Compulsive Disorder
23. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study
24. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis
25. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome
26. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis
27. Well-being in clozapine-treated schizophrenia patients: The significance of positive symptoms
28. Association of birth weight and the development of antipsychotic induced adiposity in individuals with treatment resistant schizophrenia
29. Abnormal glycemic homeostasis at the onset of serious mental illnesses: A common pathway
30. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people
31. Assessment and the concept of negative symptoms
32. Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers
33. Should obesity be a limiting factor for clozapine treatment?
34. ¿Debería considerarse la obesidad un factor limitante para el tratamiento con clozapina?
35. Eli Robins: The grandfather of DSM-III
36. The effect of early life events on glucose levels in first-episode psychosis
37. The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
38. CONSENSO POR EL COLECTIVO DE PSIQUIATRAS POR LA ACTUALIZACIÓN DE CLOZAPINA.
39. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features
40. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis
41. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients
42. Multidimensional predictors of negative symptoms in antipsychotic-naive first-episode psychosis
43. Adaptación y validación española de la Escala Pronóstica para la Esquizofrenia de Strauss y Carpenter
44. A continuous emotional task activates the left amygdala in healthy volunteers: 18FDG PET study
45. Cannabis use and age of diagnosis of schizophrenia
46. Progressive gray matter changes in first episode schizophrenia: A 4-year longitudinal magnetic resonance study using VBM
47. Differences in glucose tolerance between deficit and nondeficit schizophrenia
48. Spanish Adaptation and Validation of the Strauss-Carpenter Outcome Scale for Schizophrenia
49. Waiting for Godot or the use of biomarkers in clinical practice
50. Women Neuroscientist Disciples of Pío del Río-Hortega: the Cajal School Spreads in Europe and South America
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.